大劑量口服白消安在異基因造血干細(xì)胞移植預(yù)處理患者體內(nèi)的藥代動力doc-資料下載頁
2025-07-18 01:35本頁面
【正文】 3(7):349352[2] 鄭春梅,張玲,馮四洲,[J]. 國外醫(yī)學(xué)輸血及血液學(xué)分冊,2003,26(6):513516[3] Slattery JT，Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation[J].Ther Drug Monit ，1998，20:543~549[4] McCune JS, Gibbs JP, Slattery JT. plasma concentration monitoring of busulfan:does it improve clinical oute?[J]. Clin Pharmacokinet, 2000, 39(2):155164[5] 張善堂，方焱，屈建，等. 柱前衍生高效液相色譜法測定人血漿中白消安的濃度[J]. 中國醫(yī)院藥學(xué)雜志，2007，27（4）：458~461[6] Bullock JM，Smith PF，Booker BM，et al. Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic dtem cell transplantation[J].Ther Drug Monit, 2006,28(1):62~66[7] Hassan M，Ljungman P， Bolme P，et al. Busulfan bioavailability[J]. Blood, 1994,84(7):2144~2150[8] Grochow LB，Krivit W，Whitley CB，et al. Busulfan disposition in children[J]. Blood，75(8):1723~1727[9] BertholleBonnet V，Bleyzac N，Galambrun C，et al. Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study[J]. Ther Drug Monit,2007,29(2):177~184[10] Kusama M，Kubota T，Matsukura Y，et al. Influence of glutathione Stransferase A1 polymorphism on the pharmacokinetics of busulfan[J]. Clinica Chimica Acta,2006,368(1):93~98[11] Hassan M，Oberg G，Ehrsson H，et al. Pharmacokinetic and metabolic studies of highdose busulfan in adults[J]. Eur J Clin Pharmacol 1989,36（5）:525~530[12 Bostrom B, Enockson K, Johnson A,et al. Plasma pharmacokinetics of highdose oral busulfan in children and adults undergoing bone marrow transplantation[J]. Pediatr transplantation,2003,7():12~18[13] Takamatsu Y，Ogata K，Yamauchi K，et al. An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation[J]. Jpn J Clin Oncol,2005,35(7):400~403[14] Lindley C，Shea T，McCune J，et al. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant：assessment of a test dose and first dose strategy[J]. Anticancer Drugs，2004,15(5):453~4598 /
環(huán)評公示相關(guān)推薦
鄂ICP備17016276號-1